Rho-Kinase-IN-2 |
| رقم الكتالوجGC66050 |
إن Rho-Kinase-IN-2 (المركب 23) عبارة عن مثبط نشط عن طريق الفم وانتقائي ومركزي للجهاز العصبي (CNS) - مثبط Rho Kinase (ROCK) (ROCK2 IC50 = 3 نانومتر). يمكن استخدام Rho-Kinase-IN-2 في أبحاث Huntington' ؛ s.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2573071-18-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Rho-Kinase-IN-2 (Compound 23) is an orally active, selective, and central nervous system (CNS)-penetrant Rho Kinase (ROCK) inhibitor (ROCK2 IC50=3 nM). Rho-Kinase-IN-2 can be used in Huntington's research[1].
Rho-Kinase-IN-2 (0-10 mM, 1 hour) treatment shows an increase in AKT phosphorylation and a decrease in MYPT1 phosphorylation[1].
Western Blot Analysis[1]
| Cell Line: | A7r5 and PANC1 cells |
| Concentration: | 0-10 mM |
| Incubation Time: | 1 hour |
| Result: | Showed concentration-dependent effects, leading to an increase in AKT phosphorylation (EC50=28 nM) and a decrease in MYPT1 phosphorylation (IC50=14 nM). |
Rho-Kinase-IN-2 (oral adiministration; 10 mg/kg; 6 times; 0.5, 1, 2, 4, 8, and 12 h) treatment shows dose- and time-dependent ROCK1 and ROCK2 target engagement[1].
Rho-Kinase-IN-2 (oral adiministration; 10 or 20 mg/kg; QD or BID; 2 weeks) treatment shows excellent tolerability assessment[1].
Rho-Kinase-IN-2 (oral adiministration; 1-20 mg/kg; once) treatment shows a direct dose- and time-dependent relationship between brain exposure and MYPT1 phosphorylation status[1].
Rho-Kinase-IN-2 (oral adiministration; 10 or 20 mg/kg; once) treatment decreases in the mean arterial, systolic, diastolic blood pressure, and heart rate[1].
Rho-Kinase-IN-2 (oral adiministration; 10 mg/kg; twice a day; 90 days) treatment leads to lower-than-expected brain concentrations[1].
| Animal Model: | Male C57BL/6 mice[1] |
| Dosage: | 10 mg/kg |
| Administration: | Oral adiministration; 10 mg/kg; 6 times; 0.5, 1, 2, 4, 8, and 12 h |
| Result: | Observed dose- and time-dependent ROCK1 and ROCK2 TE, with a free brain KiNativ ROCK1 and ROCK2 IC50=∼6 nM. |
| Animal Model: | 3-4 months old heterozygote Q175DN KI and wild-type littermate mice[1] |
| Dosage: | 10 or 20 mg/kg |
| Administration: | Oral adiministration; 10 or 20 mg/kg; once a day or twice a day; 2 weeks |
| Result: | Scored neurological index normally at all doses although a slight loss in bodyweight (∼2%) in the 20 mg/kg treatment group. |
| Animal Model: | Heterozygote HTT zQ175DN knock-in mice[1] |
| Dosage: | 1-20 mg/kg |
| Administration: | Oral adiministration; 1-20 mg/kg; once |
| Result: | Remained over MYPT1 IC50 for over 2 h of the free brain at 10 mg/kg, and observed the dose- and time-dependent inhibition of MYPT1 phosphorylation in the striatum following acute in vivo dosing. |
| Animal Model: | CD1 mice[1] |
| Dosage: | 10 and 20 mg/kg |
| Administration: | Oral adiministration; 10 or 20 mg/kg; once |
| Result: | Observed the decreases in the mean arterial (maximum change of 61.0 ± 8.5 mmHg from baseline), systolic (maximum change of 59.5 ± 8.4 mmHg from baseline), diastolic blood pressure (maximum change of 56.4 ± 9.0 mmHg from baseline), and heart rate (maximum change from predose of 107 bpm) when compared to the control group from ∼0.5 to 2 h post dose. |
| Animal Model: | Heterozygote Q175DN KI mouse model of HD[1] |
| Dosage: | 10 mg/kg |
| Administration: | Oral adiministration; 10 mg/kg; twice a day; 90 days |
| Result: | Led to lower-than-expected brain concentrations compared to single dosing. |
| Cas No. | 2573071-18-6 | SDF | |
| Formula | C20H25FN4O2 | M.Wt | 372.44 |
| الذوبان | DMSO : 50 mg/mL (134.25 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.685 mL | 13.425 mL | 26.85 mL |
| 5 mM | 0.537 mL | 2.685 mL | 5.37 mL |
| 10 mM | 0.2685 mL | 1.3425 mL | 2.685 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *